Is there a place for heart-type fatty acid binding protein in the era of high-sensitive cardiac troponin T for the diagnosis of acute myocardial infarction? A systematic review

Daniel M.F. Claassens,1 Djura O. Coers,2 Thomas O. Bergmeijer,1 Dean R.P.P. Chan Pin Yin,1 Jurriën M. Ten Berg1

1Department of Cardiology, St. Antonius Hospital, Nieuwegein; 2Department of Primary Care and Elderly Care, Amsterdam Public Health Institute, Amsterdam UMC, The Netherlands

Abstract

Early recognition of myocardial infarction (MI) remains a challenge, especially in patients presenting with non-ST-segment elevation MI. Heart-type fatty acid binding protein (hFABP) has shown to be a more sensitive marker for myocardial necrosis as compared to non-high sensitive troponins (4th generation and older). However, since high sensitive troponin (hs TnT) assays are available, it is questionable whether hFABP still has value as a diagnostic tool for MI. A systematic search was conducted in Medline, Embase and Cochrane. After selecting the articles, they were assessed for risk of bias according to the QUADAS-2 criteria. Negative predictive value, positive predictive value, sensitivity and specificity were extracted or calculated if possible. Nine studies met the inclusion criteria. Overall, hs TnT showed higher sensitivity than hFABP, while hFABP had higher specificity. In patients presenting within 3 hours after onset of symptoms, sensitivity is low for both hFABP and hs TnT (19-63% vs 25-55%, respectively), while specificity seems higher for hFABP than for hs TnT (70-99% vs 57-86%, respectively). In these patients, the area under the curve for hs TnT is equal or better than that for hFABP (0.67-0.92 for hs TnT vs 0.69-0.85 for hFABP). The addition of hFABP to hs TnT did not improve sensitivity and specificity. This systematic review finds no advantage for using hFABP over hs TnT in either early presenting patients or overall. Furthermore, no advantage was found if a combination of hFABP and hs TnT was used for the diagnosis of MI.

Introduction

It is important to diagnose myocardial infarction (MI) as soon as possible, to improve the prognosis by timely intervention and reduce the time in the emergency department. However, early diagnosis of MI remains a challenge, especially in patients with non-ST-segment elevation MI (NSTEMI) or in patients presenting early after onset of symptoms. A systematic review finds no advantage for using hFABP over hs TnT in either early presenting patients or overall. Furthermore, no advantage was found if a combination of hFABP and hs TnT was used for the diagnosis of MI.
Methods of research

Search strategy

A systematic literature search was conducted using Medline, Embase and Cochrane databases of all literature until the 19th of March 2018. The search was constructed by combining high sensitive troponin t and heart type fatty acid binding protein and myocardial infarction (see the Appendix for full search). After removing duplicates, all publications were independently screened by the first two authors on title and abstract, using predetermined in- and exclusion criteria. The inclusion criteria were: diagnostic cohort study; inclusion of patients ≥18 years suspected of an acute coronary syndrome (ACS); testing of both hFABP and hs TnT prior to the diagnosis; cut-off value for hs TnT>14ng/L; and NSTEMI or a combined outcome of NSTEMI and STEMI as outcome variable. We excluded studies in which ACS, including unstable angina pectoris, was used as the primary outcome variable, studies which were not available in English or Dutch, were performed in the primary care setting, were non-human studies or if no full text version was available. We did not discriminate between studies using lab tests or point-of-care tests for determining hFABP or hs TnT.

The remaining publications were screened for full text. The references of the included publications were screened in Web of Science and Scopus to check for additional relevant publications. Any disagreement was resolved by discussion between the first three authors.

Assessment for risk of bias

All included publications were independently screened by the first three authors (DMFC, DOC, TOB) for the risk of bias, based on predefined criteria. These criteria are a modified version of the QUADAS-2 criteria for diagnostic research. We assessed whether there was more than 10% missing data, if there was standardization for how both the determinant and the outcome parameter were determined, if the blood samples for hFABP and hs TnT were collected at the same time, if there was a pre-specified cut-off value for hFABP and if the outcome assessor was blinded for the results of the hFABP test. Furthermore, we assessed whether there was a risk of bias in the inclusion process. Exclusion of STEMI patients was allowed, since it is not standard practice to test for cardiac troponin in these patients. Any disagreement was resolved by discussion between the first two authors and the third author. For each item, one point was awarded if specific criteria were met. Studies scoring six or seven points were assessed as having a low risk of bias, studies scoring four or five points were assessed as having a medium risk of bias and studies scoring less than four points were assessed as having a high risk of bias.

Data extraction and analysis

Data regarding prior probability, positive and negative predictive value (PPV and NPV), sensitivity and specificity and their 95% confidence intervals were extracted from the full text article. If these parameters were not presented, they were calculated using the available data using the statistical program ‘R’ (CRAN project) or the area under the curve (AUC) was extracted from the article if this was available. We choose not to perform a meta-analysis, due to differences in cut-off values and outcome parameters in the selected studies. We also analysed the combination of hFABP and hs TnT and compared hFABP with hs TnT in patients presenting within 3 hours after onset of symptoms.

Results

Search strategy

Our search yielded 232 unique publications, which were subsequently screened on inclusion and exclusion criteria, using the title and abstract. Of these, 35 publications were screened on full text and finally 9 publications were adjudicated for risk of bias (Figure 1). An overview of the included publications is presented in Table 1.6-14

Risk of bias assessment

Table 2 shows the risk of bias assessment.6-14 All publications were either prospective or retrospective cohort studies. One of the studies was adjudicated as having a high risk of bias, one of the studies was adjudicated as having a medium risk of bias and all other studies as having a low risk of bias.

Figure 1. Literature search results. Hs TnT, high-sensitive troponin T; hFABP, heart-type fatty acid binding protein; ACS, acute coronary syndrome.

[page 52] Emergency Care Journal 2019; 15:8049
Data analysis

Results of the studies are shown in Table 3.6-12,14 The last column specifies whether NSTEMI or MI was used as the outcome parameter. In two of the studies the NPV was significantly higher for hs TnT as compared to hFABP, while there were no significant differences in the PPV. Specificity of hFABP was significantly better in two studies, while the sensitivity of hs TnT was significantly better in one study. Overall, NPV and sensitivity seemed to be higher for hs TnT, while PPV and specificity seemed to be higher for hFABP.

Table 4 shows the results from the different studies on early presenters.9,11-13 Only the study from Schoenenberger et al. focused specifically on early presenting patients.13 Studies reporting an AUC have equal results or showed an advantage for hs TnT over hFABP. Studies reporting a PPV showed an advantage for hFABP. However, no statistical significance was either found or reported in these studies. No difference in NPV was found.

Table 1. Overview of included studies.

| Authors                      | Year of publication | Study design         | Number of patients (N) | Male (%) | Age | Time from symptom onset to presentation (hours) | hFABP cut-off value (µg/L) | Outcome parameter | Pre-specified cut-off value (µg/L) | Prevalence of outcome (%) |
|------------------------------|---------------------|----------------------|------------------------|----------|-----|-----------------------------------------------|---------------------------|-------------------|-----------------------------------|--------------------------|
| Cappellini et al.1           | 2013                | Retrospective cohort | 67                     | 67       | 74 (mean) | NA                                  | 3.49                     | NSTEMI            | 33                                |
| Eggers et al.1               | 2012                | Retrospective cohort | 360                    | 66       | 67 (mean) | <8                                  | 5.8                      | NSTEMI            | 36                                |
| Gami et al.1                 | 2015                | Prospective cohort   | 88                     | NA       | NA     | <6                                  | 5.09                     | MI                | 39                                |
| Inoue et al.9                | 2011                | Retrospective cohort | 432                    | 73       | 67 (median) | <24                                 | 6.2                      | NSTEMI            | 9                                 |
| Kellens et al.10             | 2016                | Prospective cohort   | 203                    | 81       | 63 (NA) | <24                                 | 5.3                      | MI                | 63                                |
| Kitamura et al.11            | 2013                | Prospective cohort   | 85                     | 78       | 67 (median) | <24                                 | 6.2                      | MI                | 55                                |
| Reiter et al.12              | 2013                | Prospective cohort   | 1037                   | 67       | 64 (median) | <12                                 | 4.2                      | NSTEMI            | 16                                |
| Schoenenberger et al.13      | 2016                | Prospective cohort   | 105                    | 70       | 61 (mean) | <1                                 | 4.0                      | NSTEMI            | 32                                |
| Willemsen et al.14           | 2015                | Prospective cohort   | 202                    | 78       | 62 (median) | <24                                 | 4.0                      | MI                | 17                                |

hFABP, heart-type fatty acid binding protein; NA, not available; NSTEMI, non-ST-elevated myocardial infarction; MI, myocardial infarction. *Point-of-care test used for heart-type fatty acid binding protein.

Table 2. Risk of bias analysis.

| Authors                      | Missing data | Patient selection | Standardization of determinant | Pre-specified cut-off value (µg/L) | Blood sample collection | Outcome standardization | Blinding for hFABP | Risk of bias |
|------------------------------|--------------|-------------------|--------------------------------|-----------------------------------|-------------------------|------------------------|---------------------|--------------|
| Cappellini et al.5           | +            | -                 | +                              | +                                 | +                       | +                     | +                   | Low          |
| Eggers et al.7               | -            | +                 | +                              | +                                 | +                       | +                     | +                   | Low          |
| Gami et al.3                 | NA           | -                 | +                              | +                                 | +                       | NA                    | +                   | High         |
| Inoue et al.9                | NA           | -                 | +                              | +                                 | +                       | +                     | +                   | Medium       |
| Kellens et al.10             | +            | +                 | +                              | +                                 | +                       | +                     | NA                  | Low          |
| Kitamura et al.11            | +            | +                 | +                              | +                                 | +                       | +                     | +                   | Low          |
| Reiter et al.12              | +            | -                 | +                              | +                                 | +                       | +                     | +                   | Low          |
| Schoenenberger et al.13      | +            | -                 | +                              | +                                 | +                       | +                     | +                   | Low          |
| Willemsen et al.14           | +            | +                 | +                              | -                                 | +                       | +                     | +                   | Low          |

Legend

- Missing data: + = 10% missing data; - = >10% missing data.
- Patient selection: + = No exclusion or only STEMI patients included; - = Other patients excluded.
- Standardization of determinant: + = Standardized protocol to test for hs TnT and hFABP; - = No standardized protocol to test for hs TnT and hFABP.
- Pre-specified cut-off value: + = Pre-specified cut-off value for hFABP; - = No pre-specified cut-off value for hFABP.
- Blood sample collection: + = Blood sample collected at the same time; - = Blood sample not collected at the same time.
- Outcome standardization: + = Standardized method to determine outcome; - = No standardized method to determine outcome.
- Blinding for hFABP: + = Outcome assessor blinded for hFABP result; - = Outcome assessor not blinded for hFABP result.

Low risk of bias: 6 or 7 +, medium risk of bias 4 or 5 +, high risk of bias <4 +. hFABP, heart-type fatty acid binding protein; hs TnT, high-sensitive troponin T; NA, not available; STEMI, ST-elevated myocardial infarction.

*Point-of-care test used for heart-type fatty acid binding protein.
Discussion and Conclusions

The aim of this systematic review was to study the value of hFABP as a marker for myocardial necrosis, alone or added to hs TnT. hFABP is known to rise very early after myocardial necrosis occurs (as soon as 30 minutes after onset of symptoms) and peaks in the blood after approximately 6-8 hours.15 hFABP was reported to be more specific to myocardial tissue compared to other biomarkers, like myoglobin and CK-MB.16 Compared to non-high sensitive cardiac troponins, hFABP has shown promising results for the diagnosis of MI, especially early after symptom onset.4 Multiple studies report higher sensitivity for the combination of troponin and hFABP compared to troponin alone.12,13 However, these studies and most published reviews have compared hFABP with non-high sensitive troponins instead of the (more accurate and now widely used) hs TnT.20

Though many of the studies in this review used a combined outcome of both NSTEMI and STEMI, the latter group is not routinely tested, since the ST-segment elevation on the ECG usually is enough to confirm the diagnosis of MI. In patients without these clear ECG changes, the ideal test for myocardial damage combines

Table 3. Heart-type fatty acid binding protein vs high-sensitive troponin T in patients suspected of myocardial infarction.

| Authors              | NPV (%) (95%CI) | PPV (%) (95%CI) | Specificity (%) (95%CI) | Sensitivity (%) (95%CI) | Outcome parameter |
|----------------------|----------------|----------------|-------------------------|-------------------------|------------------|
| Cappellini et al.,6   | 100 (76-100)   | 88 (69-97)    | 44 (30-60)              | 39 (25-55)              | NSTEMI           |
| Eggers et al.7        | 74 (69-79)     | 87* (81-90)   | 81 (69-90)              | 95 (91-97)              | NSTEMI           |
| Gami et al.8          | 90 (79-97)     | 94 (81-99)    | 82 (66-93)              | 88* (77-96)             | MI               |
| Inoue et al.9         | 77             | 86            | 60                      | 78                      | NSTEMI           |
| Kellens et al.10      | 52             | 61            | 85                      | 84                      | MI               |
| Kitamura et al.11     | 69 (52-81)     | 69 (52-83)    | 91 (76-98)              | 92 (79-98)              | MI               |
| Reiter et al.12       | 94 (92.95)     | 98 (97.99)    | 41 (35-47)              | 80 (77-82)              | NSTEMI           |
| Willemsen et al.13    | 94             | 93            | 36                      | 71                      | MI               |

Table 4. Heart-type fatty acid binding protein vs high-sensitive troponin T in early presenters (<3 hours since symptom onset).

| Authors              | Time to presentation (hours) | NPV (%) (95%CI) | PPV (%) (95%CI) | Specificity (%) (95%CI) | Sensitivity (%) (95%CI) | AUC (95%CI) |
|----------------------|------------------------------|----------------|----------------|-------------------------|-------------------------|-------------|
| Inoue et al.5        | 3                            | NA             | NA             | NA                      | NA                      | 0.69 (0.58-0.81) |
| Kitamura et al.11    | 2                            | 57 (34-77)     | 40 (19-64)     | 86 (42-100)             | 93 (66-100)             | 0.88 (0.82-0.94) |
| Reiter et al.12      | 3                            | NA             | NA             | 50                      | NA                      | 0.94 (0.92-0.95) |
| Schoenenberger et al.15 | 1 AUC: 2                   | 90             | 91             | 89                      | 99                      | 0.86 (0.80-0.92) |

Table 5. Combination of heart-type fatty acid binding protein and high-sensitive troponin T for the diagnosis of myocardial infarction.

| Authors              | NPV (%) (95%CI) | PPV (%) (95%CI) | Specificity (%) (95%CI) | Sensitivity (%) (95%CI) | AUC (95%CI) |
|----------------------|----------------|----------------|-------------------------|-------------------------|-------------|
| Eggers et al.7       | 87 (82-91)     | 63 (55-70)     | 75 (69-80)              | 80 (72-86)              | NA          |
| Gami et al.8         | 100            | 85             | 89                      | 100                     | NA          |
| Kellens et al.10     | 70             | 83             | 71                      | 82                      | NA          |
| Reiter et al.12      | NA             | NA             | NA                      | 0.94 (0.92-0.95)        | 0.88 (0.86-0.90) |
| Schoenenberger et al.15 | 2             | NA             | NA                      | NA                      | 0.82 (0.76-0.85) |

NPV, negative predictive value; CI, confidence interval; PPV, positive predictive value; hFABP, heart-type fatty acid binding protein; hs TnT, high-sensitive troponin T; NSTEMI, non-ST elevated myocardial infarction; MI, myocardial infarction. *Point-of-care test used for heart-type fatty acid binding protein. **Significant difference between hFABP and hs TnT.
high sensitivity with high specificity to quickly discriminate between patients who can be send home safely and patients that should be admitted and treated for MI. Our review shows that the sensitivity of hs TnT was found to be higher in six of the eight studies. However, only in two of studies the difference was significant. In the studies from Cappellini et al. and Willemesen et al., sensitivity of hFABP was found to be higher than that of hs TnT (100% vs 85% and 78% vs 73% respectively). This higher sensitivity can be explained by the low cut-off value that was used (3.49µg/L and 4.0µg/L respectively). Earlier studies have shown that the median of hFABP for patients without MI was 3.9µg/L (1.7-7.9 (interquartile range)). Consequently, this high sensitivity comes with a low specificity, especially in the study from Cappellini et al., of only 39%. This is contrary to the other studies, in which a higher specificity for hFABP is found. Since the risk of death is almost twofold when the diagnosis of MI is missed, high sensitivity is thought to be of more importance than specificity in this patient group.

In patients presenting early after symptom onset, the results of the two biomarkers are comparable. Although hFABP seems to be a valuable tool for early diagnosis, its sensitivity, even in the early hours, is not better than that of hs TnT. It must be noted that there is a wide variation in both sensitivity and specificity between different studies. However, with a sensitivity of just 50-60%, hFABP cannot replace hs TnT assays as a standalone test for the diagnosis of a MI. This finding is in line with a systematic review by Bruins Slot et al. in 2010, comparing hFABP with other biomarkers like CK, CK-MB and non-high sensitive troponins, although in this review almost half of the included studies used POC tests and/or different definitions for MI.

The three studies that reported sensitivity and specificity for the combination of high sensitive troponin T assays and hFABP all show similar or increased specificity for the combined tests. This is in contrast with our expectations, since in different reviews sensitivity increases when combined tests are performed, at the cost of a loss in specificity. For example, in a recently published article by Young et al., looking specifically at combining ECG with hs TnT and hFABP for the diagnosis of acute MI, sensitivity increased from 94.8% (ECG or hs TnT) to 97.2% (ECG or hs TnT or hFABP), while specificity decreased from 69.6% to 43.6%. The studies in our review provided no clear explanation for this discrepancy.

The comparison of hFABP to hs TnT is hampered by a major methodological problem, because hs TnT are used as the gold standard for the diagnosis of MI. Most of the studies we included for our review tried to solve this problem by using multiple independent physicians and all medical data available (including ECGs, lab results and coronary angiograms) to confirm the diagnosis of MI. However, it will be very difficult for any cardiac biomarker to outperform hs TnT. With this limitation in mind, we found no convincing evidence that hFABP, alone or in combination with hs TnT, has a better diagnostic performance compared to hs TnT, if hs TnT is easily available.

An important advantage for hFABP is the availability as point-of-care (POC) test, which can be used when classic laboratory tests like hs TnT are not available, for instance in the pre-hospital setting. However, in a review by Bruins Slot et al. published in 2013, NPV was too low to safely exclude MI diagnosis when using the hFABP POC test, although many studies were of poor quality. Also, a recently published study by Bank et al. found that the used POC test was inferior to the hs TnT test. However, newer POC tests have been introduced since, for instance from FABPulous BV (Maastricht, the Netherlands), which was used in the studies by Kellens et al. included in our review. Furthermore, POC TnT tests are being developed and first results of the newer generation tests have recently been published. Even though the limit of detection in the newer generation POC tests is less than half of that of the older generation, it is still more than tenfold higher than that of the high sensitive troponins (40ng/L and 3ng/L, respectively).

Concluding, no convincing evidence was found to support the use of hFABP instead of, or in combination with hs TnT for the diagnosis of myocardial infarction, neither in early presenting patients nor in patients presenting after more than 3 hours after onset of symptoms.

**Limitations**

There are a few limitations to this review to mention. First, different cut-off levels were used for hFABP, which has major influence on NPV, PPV, specificity and sensitivity, leading to difficulty in comparing the different studies. Second, there was a large variation in the prevalence of NSTEMI and MI between the different studies (9-63%). A higher prevalence leads to a higher PPV and a lower NPV and a different population does not only effect the prevalence, but it can also affect the sensitivity and specificity of a diagnostic test. This variation can therefore have a major influence on the results. Last, only one study specifically investigated patients presenting early after onset of symptoms. In all other studies this was only a sub-group analysis.

**References**

1. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016;37:267-315.
2. Thyesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252-7.
3. Goodacre S, Bradburn M, Cross E, et al. The RATPAC (randomised assessment of treatment using panel assay of cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technol Assess 2011;15:1-102.
4. McCann CJ, Glover BM, Menown IB, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 2008;29:2843-50.
5. Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
6. Cappellini F, Da Molin S, Signorini S, et al. Heart-type fatty acid-binding protein may exclude acute myocardial infarction on admission to emergency department for chest pain. Acute Card Care 2013;15:83-7.
7. Eggers KM, Venge P, Lindahl B. High-sensitive cardiac troponin T outperforms novel diagnostic biomarkers in patients with acute chest pain. Clin Chim Acta 2012;413:1135-40.
8. Gami BN, Patel DS, Haridas N, et al. Utility of heart-type fatty acid binding protein as a new biochemical marker for the early diagnosis of acute coronary syndrome. J Clin Diagn Res 2015;9:BC22-4.
9. Inoue K, Suwa S, Ohta H, et al. Heart fatty acid-binding protein offers similar diagnostic performance to high-sensitive cardiac markers. J Am Coll Cardiol 2012;59:237-43.
10. Kellens et al. included in our review.
troponin T in emergency room patients presenting with chest pain. Circ J 2011;75:2813-20.
10. Kellens S, Verbrugge FH, Vanmechelen M, et al. Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in emergency patients at high risk for acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2016;5:177-84.
11. Kitamura M, Hata N, Takayama T, et al. High-sensitivity cardiac troponin T for earlier diagnosis of acute myocardial infarction in patients with initially negative troponin T test—comparison between cardiac markers. J Cardiol 2013;62:336-42.
12. Reiter M, Twerenbold R, Reichlin T, et al. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. Heart 2013;99:708-14.
13. Schoenenberger AW, Stallone F, Walz B, et al. Incremental value of heart-type fatty acid-binding protein in suspected acute myocardial infarction early after symptom onset. Eur Heart J Acute Cardiovasc Care 2016;5:185-92.
14. Willemsen RT, Van Severen E, Vandervoort PM, et al. Heart-type fatty acid binding protein (H-FABP) in patients in an emergency department setting, suspected of acute coronary syndrome: optimal cut-off point, diagnostic value and future opportunities in primary care. Eur J Gen Pract 2015;21:156-63.
15. Kleine AH, Glatz JF, Van Nieuwenhoven GJ, et al. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction. Mol Cell Biochem 1992;116:155-62.
16. Glatz JF, Van der Vusse GJ, Simoons ML, et al. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta 1998;272:87-92.
17. Lippi G, Mattiuzzi C, Cervellin G. Critical review and meta-analysis of the combination of heart-type fatty acid binding protein (H-FABP) and troponin for early diagnosis of acute myocardial infarction. Clin Biochem 2013;46:26-30.
18. McMahon CG, Lamont JV, Curtin E, et al. Diagnostic accuracy of H-FABP for the early diagnosis of AMI. Am J Emerg Med 2012;30:267-74.
19. Body R, McDowell G, Carley S, et al. A FABP-ulous ‘rule out’ strategy? Heart fatty acid binding protein and troponin for rapid exclusion of AMI. Resuscitation 2011;82:1041-6.
20. Roche Diagnostics. Troponin T hs (package insert). Mannheim: Roche Diagnostics GmbH; 2013.
21. Pope HJ, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000;342:1163-70.
22. Bruins Slot MH, Reitsma JB, Rutten FH, et al. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction: a systematic review and meta-analysis. Heart 2010;96:1957-63.
23. Carroll C, Al Khalaf M, Stevens JW, et al. Heart-type fatty acid binding protein as an early marker for myocardial infarction: systematic review and meta-analysis. Emerg Med J 2013;30:280-6.
24. Young JM, Pickering JW, George PM, et al. Heart fatty acid binding protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction. BMC Emerg Med 2016;16:34.
25. Bruins Slot MH, Van der Heijden GJ, Stelpstra SD, et al. Point-of-care tests in suspected acute myocardial infarction: a systematic review. Int J Cardiol 2013;168:5355-62.
26. Bank IE, Dekkers MS, Hoes AW, et al. Suspected acute coronary syndrome in the emergency room: Limited added value of heart type fatty acid binding protein point of care or ELISA tests: The FAME-ER (Fatty Acid binding protein in Myocardial infarction Evaluation in the Emergency Room) study. Eur Heart J Acute Cardiovasc Care 2016;5:364-74.
27. Gerede DM, Gülç D, Kiliçkap M, et al. Comparison of qualitative measurement of heart-type fatty acid binding protein with other cardiac biomarkers as an early diagnostic marker in the diagnosis of non-ST segment elevation myocardial infarction. Cardiovasc J Afr 2015;26:204-9.
28. Slagman A, Von Recum J, Möckel M, et al. Diagnostic performance of a high-sensitive troponin T assay and a troponin T point of care assay in the clinical routine of an emergency department: a clinical cohort study. Int J Cardiol 2017;230:454-60.
29. Jungbauer C, Hupf J, Giannitsis E, et al. Analytical and clinical validation of a point-of-care cardiac troponin T test with an improved detection limit. Clin Lab 2017;63:633-45.
30. Leefflang MM, Rutjes AW, Reitsma JB et al. Variation of a test’s sensitivity and specificity with disease prevalence. CMAJ 2013;185:E537-44.
31. Knottnerus JA, Leffers P. The influence of referral patterns on the characteristics of diagnostic tests. J Clin Epidemiol 1992;45:1143-54.